Welcome to our dedicated page for RELIEF THERAPEUTICS S/ADR news (Ticker: RLFTY), a resource for investors and traders seeking the latest updates and insights on RELIEF THERAPEUTICS S/ADR stock.
RELIEF THERAPEUTICS Holding SA (RLFTY) is a biopharmaceutical company dedicated to developing innovative treatment options for select specialty, unmet, and rare diseases. The company's mission is to provide therapeutic relief to patients through its portfolio of revenue-generating products, proprietary Physiomimic™ and TEHCLO™ platform technologies, and a clinical development pipeline focused on rare skin, metabolic, and respiratory disorders. With a team of experienced industry leaders, Relief Therapeutics aims to optimize patient outcomes and advance treatment paradigms. Headquartered in Geneva, the company is listed on the SIX Swiss Exchange and OTCQB in the U.S.
Rhea-AI Summary
Relief Therapeutics Holding SA grants exclusive license to Eton Pharmaceuticals, Inc. for commercialization of GOLIKE products in the U.S., marking a strategic move in partnership models. The agreement includes upfront payment, sales milestones, and royalties. PKU GOLIKE's net sales exceeded $1 million in the U.S. in Q4 2023, with additional medical food line extensions for rare metabolic diseases planned for launch.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Relief Therapeutics Holding SA renews a CHF 50 million Share Subscription Facility agreement with GEM Global Yield LLC, showcasing commitment to strategic transformation. The Company aims to enhance financial flexibility and development initiatives over the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announced its intent to transition from direct marketing and sales to a partnership-based model to focus on R&D activities. The company aims to streamline its commercial operations and reinforce its foundational strengths, particularly affecting its GOLIKE® franchise. Relief remains committed to supporting patients benefiting from PKU GOLIKE® and is exploring potential partnerships for the continued commercialization and expansion of its franchise and the expected commercial launch of RLF-OD032 in early 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Relief Therapeutics Holding SA (RLF) announces the stepping down of CEO Jack Weinstein and the appointment of Michelle Lock as the interim CEO. Michelle Lock, a highly experienced pharmaceutical executive, will be taking over the role immediately. She has nearly 30 years of biopharmaceutical strategic, operational, and commercialization experience and has previously held executive roles at Covis Pharma Group and Acceleron Pharma Inc. Relief is excited to have Michelle lead the company and is looking forward to a new chapter under her leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Relief Therapeutics announces over 400,000 outstanding ADRs, a key requirement for NASDAQ listing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
RELIEF THERAPEUTICS to present at H.C. Wainwright Global Investment Conference on Sept. 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
43.45%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.89%
Tags
-
Rhea-AI Summary
Relief Therapeutics announces that its state-of-the-art laboratory in Balerna, Switzerland has been audited and approved by Swissmedic, the national authorization and supervisory authority for drugs and medical products. The laboratory meets Good Manufacturing Practice (GMP) standards and offers a comprehensive suite of analytical and development services. The lab is designed to meet forthcoming pharmaceutical challenges and is fully integrated with current R&D capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Relief Therapeutics announces implementation timeline for reverse split of its ordinary shares
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of RELIEF THERAPEUTICS S/ADR (RLFTY)?
The current stock price of RELIEF THERAPEUTICS S/ADR (RLFTY) is $4.8 as of December 19, 2024.
What is the market cap of RELIEF THERAPEUTICS S/ADR (RLFTY)?
The market cap of RELIEF THERAPEUTICS S/ADR (RLFTY) is approximately 58.3M.
What is the core focus of RELIEF THERAPEUTICS Holding SA?
RELIEF THERAPEUTICS focuses on developing innovative treatment options for select specialty, unmet, and rare diseases.
Where is RELIEF THERAPEUTICS headquartered?
RELIEF THERAPEUTICS is headquartered in Geneva with additional offices in Balerna, Switzerland, Offenbach am Main, Germany, and Monza, Italy.
What are the key areas of therapeutic focus for RELIEF THERAPEUTICS?
RELIEF THERAPEUTICS targets rare skin diseases, rare metabolic disorders, and rare respiratory diseases with its therapeutic portfolio.
What are the proprietary platform technologies of RELIEF THERAPEUTICS?
RELIEF THERAPEUTICS utilizes the globally patented Physiomimic™ and TEHCLO™ platform technologies in developing its treatment options for rare diseases.
Where is RELIEF THERAPEUTICS listed for trading?
RELIEF THERAPEUTICS is listed on the SIX Swiss Exchange under the symbol RLF and quoted on OTCQB in the U.S. under the symbols RLFTF and RLFTY.
Who leads the operational team at RELIEF THERAPEUTICS?
RELIEF THERAPEUTICS is led by an international team of experienced biopharma industry leaders with extensive research, development, and rare disease expertise.
What is the primary goal of RELIEF THERAPEUTICS?
RELIEF THERAPEUTICS aims to deliver improvements in efficacy, safety, and convenience to enhance patient outcomes and provide therapeutic relief to those suffering from rare diseases.
How does RELIEF THERAPEUTICS ensure balanced portfolio growth?
RELIEF THERAPEUTICS balances its portfolio with revenue-generating products, platform technologies, and a clinical development pipeline to drive sustainable growth and innovation.
What geographical presence does RELIEF THERAPEUTICS have?
RELIEF THERAPEUTICS has a strong presence in Geneva, Switzerland, along with offices in Balerna, Offenbach am Main, and Monza, reflecting its international focus.
How does RELIEF THERAPEUTICS approach corporate transparency?
RELIEF THERAPEUTICS maintains transparency by providing regular updates, engaging with shareholders, and aligning its strategic goals with the interests of various stakeholders to build trust and credibility.
RELIEF THERAPEUTICS S/ADR